Heart diseases-focused drug company Cytokinetics [NASDAQ:CYTK] is seeing strong interest from Novartis [NYSE:NVS] and AstraZeneca [NASDAQ:AZN] as it weighs options after receiving takeover interest, three sources familiar with the situation said.

The strategics are in a wait-and-see mode as California-based biopharmaceuticals company is expected to announce late-stage data for its experimental heart disease drug aficamten any time this month, the same sources said.

Centerview Partners is advising Cytokinetics on the sale, two of the sources said.

In addition to Novartis and AstraZeneca other strategics have also been engaging with the company as parties are expecting to see good data come out for aficamten, each of the sources said.

A breakthrough therapy Aficamten is deemed to be a potential treatment for hypertrophic cardiomyopathy, which results in the thickening of heart muscles leading to possible cardiac arrest.

If the company announces good data, discussions between the seller and interested suitors could expedite with a possible sale announcement in the near-term, the sources said.

In October, Bloomberg reported that Cytokinetics is weighing its options after receiving takeover interest. The same report said it has attracted interest from at least one major pharma company in recent months and is now evaluating its next steps. The shares have been up 7% since the sale news broke.

Interest in Cytokinetics has been good as there aren’t that many good cardiovascular drugs, one of the sources noted. He and another source said this company akins to MyoKardia, which was acquired by Bristol-Myers Squibb [NYSE: BMY] for USD 13.1bn in 2020.

Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors, according to a press release.

The company has around USD 3.7bn market cap, and it has USD 609m in debt and USD 540m in cash and short-term investments.

Cytokinetics, Novartis and Centerview Partners declined comment. AstraZeneca did not respond to request for comment.